Stem cell therapies show promise for Alzheimer’s disease, but clinical evidence remains limited

Alzheimer’s disease affects more than 55 million people worldwide, yet current pharmacological treatments deliver only modest symptomatic benefits and have limited effects on disease progression. A new review published in Behavioral and Brain Functions examines whether stem cell-based therapies could offer a regenerative alternative, and concludes that while laboratory results are encouraging, clinical evidence is still thin.

The review, authored by Saeid Najafi, Yasaman Tamaddon, Naeimeh Akbari-Gharalari, Abbas Jafari, Zahra Niknam and colleagues, was published on 5 October 2026 as an open-access article. It surveys four main therapeutic modalities: mesenchymal stem cells (MSCs), neural stem cells (NSCs), products derived from induced pluripotent stem cells (iPSCs), and the extracellular vesicles (EVs) that these cells release.

According to the authors, experimental studies suggest these approaches may act through several complementary mechanisms at once. The candidate therapies appear to modulate neuroinflammation, oxidative stress, apoptosis, neurogenesis and synaptic plasticity, processes that are all implicated in the progression of Alzheimer’s disease. This multi-target character is one reason stem cell strategies have attracted attention as potential regenerative treatments rather than purely symptomatic ones.

Among the modalities reviewed, extracellular vesicles have drawn increasing interest. The review highlights three advantages: lower immunogenicity than whole-cell therapies, a reduced risk of tumorigenesis, and a potential ability to cross the blood–brain barrier, the selective boundary that complicates delivery of most drugs and cells to the brain.

Encouraging results so far come overwhelmingly from preclinical models. The authors note that these therapies have demonstrated promising outcomes in laboratory and animal studies, but they are careful to distinguish this from demonstrated benefit in patients.

That distinction matters because the clinical picture is far less developed. Published trials to date have primarily evaluated safety and feasibility rather than therapeutic efficacy, meaning that whether these treatments can actually slow or alter the course of Alzheimer’s disease in people remains an open question.

The review also identifies major translational challenges that continue to impede clinical application. These include limited brain delivery, difficulties in manufacturing standardization, incomplete product characterization, and unresolved questions about long-term safety. Each of these obstacles must be addressed before stem cell or EV-based therapies can move confidently into larger efficacy trials.

The authors frame the article as a summary of current mechanistic evidence, a critical discussion of translational limitations, and a set of future research priorities intended to support clinical development. The published version is a peer-reviewed, accepted manuscript shared early to provide faster access, and is subject to further edits before the final version of record.

For now, the takeaway from the review is measured: stem cell-derived therapies represent a biologically plausible and mechanistically rich avenue for Alzheimer’s disease research, with extracellular vesicles emerging as a particularly interesting delivery strategy, but the field has not yet produced the clinical efficacy data needed to change patient care.

Subject of Research: Stem cell-based and extracellular vesicle therapies for Alzheimer's disease: mechanisms, translational challenges and future research priorities

Article Title: Harnessing stem cell-based therapies for Alzheimer’s disease: mechanism, challenges, and future perspectives

Article References: Najafi, S., Tamaddon, Y., Akbari-Gharalari, N., Jafari, A., & Niknam, Z. (2026). Harnessing stem cell-based therapies for Alzheimer’s disease: mechanism, challenges, and future perspectives. Behavioral and Brain Functions. https://doi.org/10.1186/s12993-026-00370-w

Image Credits: AI Generated

DOI: 10.1186/s12993-026-00370-w

Keywords: Alzheimer's disease, stem cell therapy, mesenchymal stem cells, neural stem cells, induced pluripotent stem cells, extracellular vesicles, neuroinflammation, synaptic plasticity, blood-brain barrier, clinical translation, regenerative medicine, review